Since 2018, numerous IL-23 inhibitors have proved their efficacy and safety in the treatment of psoriasis and peripherical psoriatic arthritis, such as guslkumab, risankizumab, and tildrakizumab [10]. Here, IL37 is linked to psoriasis.